- Investopedia•10 days ago
The company’s ESMO presentation gives insight into latest analyst recommendations, offers potential for cautious optimism among investors.
- PR Newswire•17 days agoCytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress
Of the 36 evaluable patients receiving either 170mg/m2 or 250mg/m2 of aldoxorubicin plus ifosfamide and mesna, 13 of 36 (36%) achieved a partial response of the target lesion by RECIST 1.1 criteria, 22 of 36 (61%) had stable disease, and one patient had progressive disease. The trial has been expanded to allow continued enrollment of additional sarcoma patients at the 250 mg/m2 dose of aldoxorubicin with ifosfamide and mesna. "The results to date demonstrate that aldoxorubicin combined with ifosfamide provides significant clinical benefit for sarcoma patients," said Sant Chawla, M.D., F.R.A.C.P., the trial's principal investigator and Director of the Sarcoma Oncology Center in Santa Monica, California.
- Accesswire•last monthDEADLINE TOMORROW ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against CytRx Corporation and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
IRVINE, CA / ACCESSWIRE / September 22, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit was filed against CytRx Corporation ("CytRx" or the "Company") ...
CytRx Corporation (CYTR)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||0.49 x 2400|
|Ask||0.49 x 500|
|Day's Range||0.49 - 0.50|
|52wk Range||0.45 - 3.66|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.54|
|Avg Vol (3m)||1,216,078|
|Dividend & Yield||N/A (N/A)|